share_log

Oppenheimer Reiterates Outperform on Astria Therapeutics, Maintains $30 Price Target

Benzinga ·  Jun 8, 2023 07:52

Oppenheimer analyst Hartaj Singh reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment